New Fund Launch
Ginward and EMBL Ventures are joining forces to launch a cross border expansion capital fund that primarily invests in Europe and Asia.
Our new fund will focus on cell and gene therapies, next-generation biologics, and their enabling technologies such as advanced manufacturing, bioinformatics, and AI.
European Life Sciences Growth Fund
‘Best of Europe’ Life Science Companies for growth into Asia
European Life Sciences Growth Fund SP builds on the huge potential for Life Sciences offered by the Asian markets, by providing funds to dynamic European companies in the sector and helping them grow in Asia.
By targeting companies that have confirmed commercial successes in their home market, the Fund focuses on those with the best chance of benefiting from an early connection to Asia.
With a management team based in Singapore and a panel of experts covering Europe and Asia, the Fund offers a specialized strategy for value creation, building on experience, well-recognized global trends and best-in-class innovation.
The success of the Fund will ensure that investors are rewarded for capitalising on opportunity, whilst funding the spread of new technologies and treatments to Asia, improving the lives of a wider population. By supporting young Life Science companies at a crucial stage in their development, the Fund is also playing its part in fostering European innovation and entrepreneurship in the sector
Portfolio Companies
Mimetas
- OrganoPlate® Patented Organ-on-a-Chip
- Microfluidic 3D Cell/Tissue Culture Technology
BiosanaPharma
- Fully Continuous, Small Footprint and High Yield Manufacturing Process for MAbs with proprietary pipeline of biologics
BiOraliX
- Proprietary Oral Formulation of mAbs and other large Proteins
Dynamic Biosensors
- Provider of instruments, consumables, and services in the field of analytical systems for the characterization of biomolecules and molecular interactions.
- switchSENSE®, a groundbreaking platform technology for the analysis of biomolecules with applications in R&D and drug development.